tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Singh K et al. | Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. | 2014 | Am. J. Transplant. | pmid:25359003 |
| Dugast E et al. | Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. | 2016 | Am. J. Transplant. | pmid:27367750 |
| Tang Q | Pharmacokinetics of therapeutic Tregs. | 2014 | Am. J. Transplant. | pmid:25358900 |
| Wen X et al. | Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients. | 2016 | Am. J. Transplant. | pmid:27137884 |
| Sikma MA et al. | Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation. | 2015 | Am. J. Transplant. | pmid:26053114 |
| Ellis CL and Racusen LC | Mild rise in creatinine six months post kidney transplant. | 2012 | Am. J. Transplant. | pmid:22845913 |
| de Fontbrune FS et al. | Veno-occlusive disease of the liver after lung transplantation. | 2007 | Am. J. Transplant. | pmid:17697264 |
| Abdelmalek MF et al. | Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. | 2012 | Am. J. Transplant. | pmid:22233522 |
| Boudjema K et al. | Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. | 2011 | Am. J. Transplant. | pmid:21466650 |
| Gupta G et al. | Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction. | 2015 | Am. J. Transplant. | pmid:25988397 |
| Wang Q et al. | Biodegradable microsphere-loaded tacrolimus enhanced the effect on mice islet allograft and reduced the adverse effect on insulin secretion. | 2004 | Am. J. Transplant. | pmid:15084166 |
| Schubert M et al. | Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. | 2004 | Am. J. Transplant. | pmid:15084173 |
| ter Meulen CG et al. | Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. | 2004 | Am. J. Transplant. | pmid:15084178 |
| Hernández-Fisac I et al. | Tacrolimus-induced diabetes in rats courses with suppressed insulin gene expression in pancreatic islets. | 2007 | Am. J. Transplant. | pmid:17725683 |
| Suszynski TM et al. | Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation. | 2013 | Am. J. Transplant. | pmid:23432755 |
| Ferguson R et al. | Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. | 2011 | Am. J. Transplant. | pmid:21114656 |
| Artz MA et al. | Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. | 2004 | Am. J. Transplant. | pmid:15147428 |
| Klintmalm GB | Immunosuppression, generic drugs and the FDA. | 2011 | Am. J. Transplant. | pmid:21794082 |
| Böger CA et al. | Reverse diastolic intrarenal flow due to calcineurin inhibitor (CNI) toxicity. | 2006 | Am. J. Transplant. | pmid:16889550 |
| Shihab FS et al. | Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study. | 2013 | Am. J. Transplant. | pmid:23167508 |
| Forns X and Navasa M | Cyclosporine A or tacrolimus for hepatitis C recurrence? An old debate. | 2011 | Am. J. Transplant. | pmid:21797970 |
| Tan HP et al. | Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. | 2006 | Am. J. Transplant. | pmid:16889606 |
| Wlodarczyk Z et al. | Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. | 2009 | Am. J. Transplant. | pmid:19681813 |
| Chisholm-Burns MA et al. | Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients. | 2009 | Am. J. Transplant. | pmid:19681814 |
| Schold JD and Kaplan B | AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients. | 2009 | Am. J. Transplant. | pmid:19681827 |
| Pillebout E et al. | Renal histopathological lesions after orthotopic liver transplantation (OLT). | 2005 | Am. J. Transplant. | pmid:15816895 |
| Gregoor PS and Weimar W | Tacrolimus and pure red-cell aplasia. | 2005 | Am. J. Transplant. | pmid:15636632 |
| Busque S et al. | Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. | 2009 | Am. J. Transplant. | pmid:19660021 |
| Gao R et al. | Effects of immunosuppressive drugs on in vitro neogenesis of human islets: mycophenolate mofetil inhibits the proliferation of ductal cells. | 2007 | Am. J. Transplant. | pmid:17391142 |
| Tremblay S et al. | A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. | 2017 | Am. J. Transplant. | pmid:27340950 |
| De Simone P et al. | Everolimus with reduced tacrolimus in liver transplantation. | 2013 | Am. J. Transplant. | pmid:23601137 |
| Chen G et al. | A synergistic effect between PG490-88 and tacrolimus prolongs renal allograft survival in monkeys. | 2006 | Am. J. Transplant. | pmid:16539628 |
| Mazariegos GV et al. | Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. | 2005 | Am. J. Transplant. | pmid:15643991 |
| Knechtle SJ et al. | Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. | 2009 | Am. J. Transplant. | pmid:19344431 |
| Bahra M et al. | MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. | 2005 | Am. J. Transplant. | pmid:15644002 |
| van Hooff JP et al. | Glucose metabolic disorder after transplantation. | 2007 | Am. J. Transplant. | pmid:17511670 |
| Toso C et al. | Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol. | 2006 | Am. J. Transplant. | pmid:16611343 |
| Tedesco-Silva H et al. | Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses. | 2015 | Am. J. Transplant. | pmid:25988935 |
| Pech T et al. | Intestinal regeneration, residual function and immunological priming following rescue therapy after rat small bowel transplantation. | 2012 | Am. J. Transplant. | pmid:22974463 |
| Kaplan B and Kirk AD | Tacrolimus and sirolimus: when bad things happen to good drugs. | 2006 | Am. J. Transplant. | pmid:16827845 |
| McAlister VC et al. | Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. | 2006 | Am. J. Transplant. | pmid:16827858 |
| Gallon L et al. | Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. | 2006 | Am. J. Transplant. | pmid:16827862 |
| Grenda R et al. | A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. | 2006 | Am. J. Transplant. | pmid:16827869 |
| Vanhove T et al. | High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. | 2016 | Am. J. Transplant. | pmid:27013142 |
| Barbas AS et al. | Posterior reversible encephalopathy syndrome independently associated with tacrolimus and sirolimus after multivisceral transplantation. | 2013 | Am. J. Transplant. | pmid:23331705 |
| Gatault P et al. | Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. | 2017 | Am. J. Transplant. | pmid:27862923 |
| Fujishiro J et al. | Influence of immunosuppression on alloresponse, inflammation and contractile function of graft after intestinal transplantation. | 2010 | Am. J. Transplant. | pmid:20642681 |
| Martinez F et al. | High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study. | 2010 | Am. J. Transplant. | pmid:20642691 |
| Miller LW | Cardiovascular toxicities of immunosuppressive agents. | 2002 | Am. J. Transplant. | pmid:12392286 |
| Brennan DC et al. | Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. | 2005 | Am. J. Transplant. | pmid:15707414 |